Loading
IP
Inozyme Pharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Aug 2023.
Inozyme Pharma, Inc.: what insiders have been doing
Inozyme Pharma, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Inozyme Pharma, Inc. has published a filing in the past twelve months. The most recent one dates from 3 July 2025.
Over the whole record (from 2021), the tally stands at 10 purchases and no sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€12M
10 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$87.8M
Last declaration on 3 July 2025
Declarations34 total
423,926 shares@ US$4.0076.6% of flowCommon StockSEC:0000950170-25-094096:0
43,861 shares@ US$4.0094.5% of flowCommon StockSEC:0000950170-25-094091:0
2,923,110 shares@ US$4.0058.3% of flowCommon StockSEC:0000950170-25-094089:0
39,701 shares@ US$4.0055.3% of flowCommon StockSEC:0000950170-25-094103:0
21,743 shares@ US$4.0072.8% of flowCommon StockSEC:0000950170-25-094098:0
14,355 shares@ US$0.749.0% of flowCommon StockSEC:0000950170-25-090868:0
2,815 shares@ US$0.741.1% of flowCommon StockSEC:0000950170-25-090864:0
6,813 shares@ US$0.741.8% of flowCommon StockSEC:0000950170-25-090862:0
152,823 shares@ US$0.987.1% of flowCommon StockSEC:0000950170-25-075148:0
25,000 sharesCommon StockSEC:0000950170-25-050443:0
2,490 shares@ US$0.770.7% of flowCommon StockSEC:0000950170-25-049386:0
2,490 shares@ US$0.771.8% of flowCommon StockSEC:0000950170-25-049393:0
1,710 shares@ US$4.456.8% of flowCommon StockSEC:0000950170-24-112694:0
1,710 shares@ US$4.454.3% of flowCommon StockSEC:0000950170-24-112695:0
25,000 sharesCommon StockSEC:0000950170-24-041301:0
3,188 shares@ US$3.339.7% of flowCommon StockSEC:0000950170-24-041300:0
2,319 shares@ US$3.573.2% of flowCommon StockSEC:0001209191-23-051393:0
119,048 shares@ US$4.8012.4% of flowCommon StockSEC:0000950170-23-038272:0
Canonical exit: 30 Oct 2023 (T+90)
▲
Same trade as the filing by Pivotal bioVenture Partners Fund I, L.P., counted once · View ↗
119,048 shares@ US$4.803.1% of flowCommon StockSEC:0000950170-23-038268:0
Canonical exit: 30 Oct 2023 (T+90)
219,230 shares@ US$6.487.7% of flowCommon StockSEC:0001209191-23-029521:0
Canonical exit: 9 Aug 2023 (T+90)
4,806 shares@ US$2.210.5% of flowCommon StockSEC:0001209191-23-022467:0
979 shares@ US$2.210.8% of flowCommon StockSEC:0001209191-23-022466:0
344,592 shares@ US$4.53798.5% of flowCommon StockSEC:0001209191-23-021647:0
Canonical exit: 27 Jun 2023 (T+90)
51,074 shares@ US$3.69521.0% of flowCommon StockSEC:0001209191-23-021559:0
Canonical exit: 25 Jun 2023 (T+90)
21,500 shares@ US$1.3921.8% of flowCommon StockSEC:0001209191-22-061766:0
Canonical exit: 15 Mar 2023 (T+90)
25 of 34 declarations
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc. is a U.S.-based clinical-stage biopharmaceutical company that was historically listed on the Nasdaq Global Select Market (NASDAQ) under the ticker INZY. The company focused on developing therapies that target the PPi-Adenosine Pathway, a biological pathway that plays an important role in bone health and blood vessel function. From an equity analysis perspective, Inozyme sat in a niche rare-disease biotechnology segment, where scientific barriers are high, development timelines are long, and value creation is heavily dependent on clinical execution and regulatory success.
The company was built around a single lead program, INZ-701, an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate (PPi) and adenosine levels. In recent corporate disclosures, INZ-701 was described as being in late-stage clinical development for ENPP1 Deficiency, with potential expansion into additional indications where PPi-Adenosine pathway deficiencies contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. That makes Inozyme a classic single-asset biotech story: high upside if the asset succeeds, but meaningful concentration risk given the lack of a diversified commercial portfolio.
Read moreShow less
Inozyme’s headquarters were in Boston, Massachusetts, at 321 Summer Street, Suite 400, placing it in one of the most important life-sciences clusters in the United States. The company’s business model was research- and development-driven rather than sales-driven; it had not yet commercialized products, and its market position was defined by the novelty of its science rather than by revenue scale. Its competitive advantage stemmed from its focus on a biologically validated pathway, its specialization in rare genetic diseases, and the possibility of becoming a first-in-class or best-in-class therapy in ENPP1 Deficiency if development and approval milestones were achieved.
A major recent event was the acquisition by BioMarin Pharmaceutical Inc. BioMarin announced the deal on May 16, 2025 and completed the acquisition on July 1, 2025. The transaction was structured as an all-cash acquisition at $4.00 per share, and it effectively ended Inozyme’s life as an independent public company. For investors, that matters for two reasons: first, it confirms that Inozyme’s lead asset had strategic value to a larger rare-disease platform; second, it means that any SEC Form 4 insider transactions around that period should be interpreted in the context of merger-related vesting, cancellations, and cash-out events rather than ongoing public-company ownership changes. In short, Inozyme was a U.S. Nasdaq-listed rare-disease biotech, based in Boston, whose main investment thesis centered on INZ-701 until it was absorbed into BioMarin’s enzyme therapy portfolio.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
